Enhua Pharmaceutical (002262.SZ) signed an exclusive commercial cooperation agreement with Luye Pharmaceutical and its subsidiaries

Zhitong Finance App News, Enhua Pharmaceutical (002262.SZ) issued an announcement. Jiangsu Enhua Hexin Pharmaceutical Marketing Co., Ltd. (hereinafter referred to as “Enhua Hexin”), a wholly-owned subsidiary of the company, reached an “Exclusive Commercial Cooperation Agreement” with Shandong Luye Pharmaceutical Co., Ltd. (hereinafter referred to as “Luye Jiao”) and its subsidiary Luye Jiao Pharmaceutical Shijiazhuang Co., Ltd. (hereinafter referred to as “Luye Jiao”), respectively.

Enhua Hexin will each receive exclusive rights to promote, sell and commercialize three antipsychotic drug long-acting injection products from Luye Pharmaceutical in mainland China: injectable risperidone microspheres (II) (hereinafter referred to as “Recotul®”), paliperidone palmitate injection (II) (hereinafter referred to as “Rabilai®”), and Luye Jiao's paliperidone palmitate injection (hereinafter referred to as “Mibirui®”).

As consideration for the rights and licenses granted by Luye Pharmaceuticals and Luye Jiao in accordance with the Agreement, Enhua Huxin shall pay Luye Pharmaceuticals and Luye Jiao a total of 20 million US dollars in a single non-refundable license consideration. The authorized consideration shall all be paid by Enhua Hexin using its own or self-funded funds. According to the “Agreement”, Enhua Hexin will complete a total sales volume of not less than RMB 2.7 billion (tax included) for Luye Pharmaceutical and Luye Jiao products during the period 2026-2035. Luye Pharmaceutical and Luye Jiao shall pay corresponding service fees to Enhua Hexin based on the procurement and sales of licensed products by Enhua Hexin.

This time, the three long-acting injections, which have received exclusive commercial rights from Luye Pharmaceutical and Luye Jiao in mainland China, form a differentiated product portfolio, which can fully cover the treatment needs of patients with schizophrenia at all stages of the course of the disease, and have significant clinical value. Central nervous system (CNS) is one of the company's core strategic areas. The company has reached a strategic cooperation with Luye Pharmaceutical and Luye Jiao, marking a strong alliance between two leading domestic companies in the central nervous system (CNS) field. The two sides will jointly promote the in-depth layout of the schizophrenia treatment market, which is conducive to improving the coverage of these products in primary medical centers, helping more patients receive standardized treatment and reduce the burden of disease.